Item no. |
HY-12037A-100mg |
Manufacturer |
MedChem Express
|
CASRN |
592542-59-1 |
Amount |
100 mg |
Quantity options |
100 mg
10mM/1mL
10 mg
50 mg
5 mg
|
Category |
|
Type |
Inhibitors |
Specific against |
other |
Purity |
98.35 |
Formula |
C21H25NO8S |
Citations |
Harvard Medical School LINCS LIBRARY<br/>Int J Biol Sci. 2020 Jun 27;16(13):2382-2391.<br/>Oncol Res. 2021 Feb 11.<br/>Sci Rep. 2017 Aug 17;7(1):8629. <br/>Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.<br/>Harvard Medical School LINCS LIBRARY<br/>[1]Xu F, et al. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signalingtransduction pathways in high-grade myelodysplastic syndrome. Sci Rep. 2014 Dec 4;4:7310.<br/>[2]Hyoda T, et al. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. Cancer Sci. 2015 Mar;106(3):287-93.<br/>[3]Gumireddy K, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell. 2005 Mar;7(3):275-86.<br/>[4]Reddy MV, et al. Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity. J Med Chem. 2011 Sep 22;54(18):6254-76.<br/>[5]Chapman CM, et al. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res. 2012 Apr 1;18(7):1979-91 |
Smiles |
COC1=CC=C(C=C1NCC(O)=O)CS(/C=C/C2=C(C=C(C=C2OC)OC)OC)(=O)=O |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
ON-01910 |
Available |
|
Product Description |
Rigosertib (ON-01910) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3 kinase/Akt pathway, promots the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle[1][2]. Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM[3]. |
StorageTemperature |
-20°C (Powder, stored under nitrogen) |
Shipping |
Blue Ice |
Manufacturers Applications |
Cancer-Kinase/protease |
MolecularWeight |
451.49 |
Clinical Information |
Phase 3 |
Manufacturers Research Area |
Cancer |
Solubility |
DMSO : 75 mg/mL (ultrasonic) |
Target |
Apoptosis; PI3K; Polo-like Kinase (PLK) |
Manufacturers Target |
Apoptosis; PI3K; Polo-like Kinase (PLK) |
Isoform |
PLK1; PLK2 |
Manufacturers Pathway |
Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR |
Manufacturers Product type |
Reference compound |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.